How to buy Biogen stock

Biogen Inc is a drug manufacturers-general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 9,100 staff and has a trailing 12-month revenue of around 0.00.

Biogen share price

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$223.25 - $335.00
50-day moving average	$268.69
200-day moving average	$263.87
Wall St. target price	$286.97
PE ratio	13.9505
Dividend yield	N/A (0%)
Earnings per share (TTM)	$19.29

Buy Biogen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biogen Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Biogen under- or over-valued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Biogen shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.2 billion.

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

Biogen financials

Revenue TTM	$12.6 billion
Operating margin TTM	29.4%
Gross profit TTM	$11.6 billion
Return on assets TTM	9.27%
Return on equity TTM	26.49%
Profit margin	23.89%
Book value	$70.93
Market capitalisation	$40.5 billion

TTM: trailing 12 months

Shorting Biogen shares

There are currently 3.2 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 11.1% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.

Biogen's "short interest ratio" (SIR)

Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.1 million). Biogen's SIR currently stands at 2.98. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2980 shares are currently held short.

However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.0242% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 24 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.

Find out more about how you can short Biogen stock.

Biogen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Biogen's total ESG risk score

Total ESG risk: 22.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Biogen's environmental score

Environmental score: 1.02/100

Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Biogen's social score

Social score: 13.48/100

Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Biogen's governance score

Governance score: 7.45/100

Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Biogen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Biogen Inc was last rated for ESG on: 2019-01-01.

Total ESG score	22.95
Total ESG percentile	33.82
Environmental score	1.02
Environmental score percentile	2
Social score	13.48
Social score percentile	2
Governance score	7.45
Governance score percentile	2
Level of controversy	2

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $223.25 up to $335. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.4368. This would suggest that Biogen's shares are less volatile than average (for this exchange).

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups.

Frequently asked questions

• What percentage of Biogen is owned by insiders or institutions?

  Currently 0.634% of Biogen shares are held by insiders and 87.782% by institutions.

• How many people work for Biogen?

  Latest data suggests 9,100 work at Biogen.

• When does the fiscal year end for Biogen?

  Biogen's fiscal year ends in December.

• Where is Biogen based?

  Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142

• What is Biogen's ISIN number?

  Biogen's international securities identification number is: US09062X1037

• What is Biogen's CUSIP number?

  Biogen's Committee on Uniform Securities Identification Procedures number is: 09062X103